Free Trial
NYSE:BIO

Bio-Rad Laboratories Q2 2025 Earnings Report

Bio-Rad Laboratories logo
$246.31 -3.34 (-1.34%)
As of 03:59 PM Eastern

Bio-Rad Laboratories EPS Results

Actual EPS
N/A
Consensus EPS
$1.98
Beat/Miss
N/A
One Year Ago EPS
N/A

Bio-Rad Laboratories Revenue Results

Actual Revenue
N/A
Expected Revenue
$614.82 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bio-Rad Laboratories Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, July 31, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

Bio-Rad Laboratories Earnings Headlines

Wall Street Zen Downgrades Bio-Rad Laboratories (NYSE:BIO) to Hold
Miss This Window And You Miss Everything
There’s a moment in every crypto cycle when everything just clicks — and that moment is now. This is the phase when momentum builds, news turns bullish, and markets ignite. Inside The Crypto Code Workshop, you’ll get the roadmap to ride this wave — and $10 in free Bitcoin just for showing up.
Equities Analysts Offer Predictions for BIO Q2 Earnings
Q2 EPS Forecast for Bio-Rad Laboratories Reduced by Analyst
See More Bio-Rad Laboratories Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bio-Rad Laboratories? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bio-Rad Laboratories and other key companies, straight to your email.

About Bio-Rad Laboratories

Bio-Rad Laboratories (NYSE:BIO) is a global provider of life science research and clinical diagnostic products, headquartered in Hercules, California. Founded in 1952 by David and Alice Schwartz, the company has grown to become a leading innovator in tools and technologies used by researchers, pharmaceutical companies, hospitals and clinical laboratories worldwide. Bio-Rad’s portfolio spans instruments, consumables, reagents and software solutions designed to accelerate scientific discovery and improve patient diagnostic outcomes.

In its Life Science segment, Bio-Rad offers a broad array of systems and reagents for applications such as gene expression analysis, protein purification and characterization, cell biology, and digital PCR. Key offerings include real-time PCR platforms, electrophoresis and imaging systems, chromatography resins, and multiplex immunoassays. Researchers across academic institutions, biotech and pharmaceutical companies rely on Bio-Rad’s products to support workflows from basic research through to drug development.

The Clinical Diagnostics segment provides quality control materials, assays and instruments for blood transfusion services, immunology and molecular testing. Bio-Rad’s diagnostic solutions help ensure the accuracy and reliability of laboratory testing for disease screening, blood donor safety and patient care. The company also supplies molecular diagnostic kits for detection of infectious diseases and employs high‐throughput technologies to support screening programs in hospitals and blood banks.

Operating in over 35 countries, Bio-Rad serves a diverse customer base across North America, Europe, Asia Pacific, Latin America and the Middle East. The company’s leadership includes members of the founding Schwartz family, with Norman Schwartz serving as Executive Chairman and Chief Executive Officer, supported by a seasoned management team. Continual investment in research and development, combined with global manufacturing and service capabilities, underpins Bio-Rad’s commitment to advancing life science research and clinical diagnostics.

View Bio-Rad Laboratories Profile

More Earnings Resources from MarketBeat